MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/1750743x.2026.2665031

Медицинская библиотека · Immunotherapy · 2026

Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials.

Vatvani Akhil Deepak, Lazarus Gilbert, Al Jabiri Reyad, Nada Rama, Albuja Altamirano Maria, Choi Eunhee, Shabarek Nehad

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

INTRODUCTION

Pembrolizumab plus chemotherapy is widely used as first-line treatment for advanced NSCLC, but its benefit in patients with low PD-L1 expression remains uncertain. This study evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in advanced or metastatic NSCLC with PD-L1 <50%.

METHODS

PubMed, Scopus, and Cochrane databases were searched for randomized controlled trials up to 17 September 2025. Primary outcomes were overall survival (OS) and progression-free survival (PFS).

RESULTS

Four randomized controlled trials (n = 2,413) were included. Pembrolizumab plus chemotherapy improved overall survival (HR 0.67, 95% CI 0.46-0.96), while progression-free survival showed a non-significant trend (HR 0.66, 95% CI 0.42-1.03). Subgroup analyses by PD-L1 (<1% and 1-49%) showed borderline, non-significant effects. Objective response rate was higher overall (RR 1.75, 95% CI 1.13-2.70) but not significant by subgroup, with moderate heterogeneity. Certainty of evidence was low. Safety outcomes were not pooled; available data suggested similar adverse events but higher immune-related toxicity and numerically higher treatment-related deaths.

CONCLUSIONS

Pembrolizumab plus chemotherapy may improve survival in advanced NSCLC with low PD-L1 expression, but benefits were inconsistent across subgroups and limited by imprecision and heterogeneity. Safety data remain limited and should be interpreted cautiously.

Для цитирования: Vatvani Akhil Deepak, Lazarus Gilbert, Al Jabiri Reyad, Nada Rama, Albuja Altamirano Maria, Choi Eunhee, Shabarek Nehad. Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials.. Immunotherapy. 2026. DOI: 10.1080/1750743x.2026.2665031.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.